ClinicalTrials.gg
Not yet recruitingNCT07935265DUAL-PVCUpdated Nov 13, 2026

Dual Energy Focal Ablation of Premature Ventricular Complexes

An interventional study of Dual Energy THERMOCOOL SMARTTOUCH™ SF (STSF) Bi-Directional Navigation catheter with TRUPULSE™ Generator in Premature Ventricular Contractions, sponsored by Konstantinos Siontis. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Konstantinos Siontis · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Ventricular Premature Complexes with a site in United States — 11 open to participants now, 12 under way, none of them phase 3. Ventricular Premature Complexes · United States.

Planned enrollment
9th of 20
60 · median 60
Started
2027
the only one that year
No phase
12 of 33
3 open now
Primary completion
2029-01
later than 9 of 11 live
Registered
33rd of 33
by date

Among the 33 studies in Ventricular Premature Complexes with a site in United States, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2027, is one of 12 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 33rd registered.

Ventricular Premature Complexes

103 studies on the registry are indexed under Ventricular Premature Complexes; 33 are open to participants now.

Browse Ventricular Premature Complexes studies →

Open to participants now

11 of the 33 studies in Ventricular Premature Complexes with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Ventricular Premature Complexes studies recruiting now, 17 (77%) set no upper age limit and 3 (14%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Ventricular Premature Complexes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to understand whether a dual-energy catheter ablation system that uses radiofrequency (RF) and pulsed-field (PF) energy can safely and effectively treat premature ventricular contractions (PVCs).

03

Conditions studied

  • Premature Ventricular Contractions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥10% burden of the target PVC on ambulatory rhythm monitoring within 3 months prior to enrollment. The qualifying ambulatory monitor may be of any duration (1-30 days) per standard of care and may be distinct from the baseline 12-lead Holter required within 30 days before ablation
  • Guideline-supported indication for first-time or redo catheter ablation of PVCs at the judgment of the electrophysiologist. Specifically:

    • Patients with symptomatic PVCs for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference.
    • Suspected or confirmed PVC-induced cardiomyopathy
    • Enrollment of patients requiring a redo procedure will be capped at 30% of planned enrollment (n=18) if the target PVC is the same or similar to that targeted in previous procedure(s), per review of the study investigator
  • Patients with and without known structural heart disease are eligible
  • Ability to undergo study-directed cardiac MRI pre- and post-procedure
  • Ability to undergo study-directed post-ablation coronary CT angiography
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • \<35%
  • class IV
  • Presence of multifocal PVCs (>=3 distinct morphologies) on available pre-baseline standard-of-care ambulatory monitor and tracings per the review of the study team.
  • PVCs attributable to a reversible or non-cardiac cause (e.g., electrolyte imbalance or active thyroid disease).
  • History of sustained VT or VF.
  • Current or recent (\<4 weeks) decompensated heart failure.
  • Active systemic infection.
  • to LGE-MRI or contrast CT.
  • Known allergy to iodinated contrast dye that cannot be adequately managed with pre-medication protocol.
  • Thrombocytopenia ( count \<50,000/mm³) or known coagulopathy.
  • Contraindication to systemic anticoagulation.
  • Severe valvular disease requiring future intervention.
  • Mechanical valve prosthesis.
  • Pregnancy.
  • Recent acute coronary syndrome (\<6 months).
  • Un-revascularized coronary artery disease.
  • Presence of left ventricular assist device (LVAD) or transplanted heart.
  • Presence of intracardiac thrombus.
  • Current use of inotropes.
  • Recent stroke or (\<6 months).
  • Presence of a systemic illness likely to limit survival to \<1 year.
  • Patient enrollment in other clinical study that could conflict with the current investigation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    RF-PF Sequential Ablation

    Participants are assigned to receive radiofrequency (RF) followed by pulsed-field (PF) at each selected treatment site. For each PF treatment, 24 PF bursts are delivered. Up to three stacked lesions may be performed at the same location.

    Device: Dual Energy THERMOCOOL SMARTTOUCH™ SF (STSF) Bi-Directional Navigation catheter with TRUPULSE™ Generator

  • Experimental
    PF-Only Ablation

    Participants are assigned to receive pulsed-field (PF) alone at each selected treatment site. For each PF treatment, 24 PF bursts are delivered. Up to three stacked lesions may be performed at the same location.

    Device: Dual Energy THERMOCOOL SMARTTOUCH™ SF (STSF) Bi-Directional Navigation catheter with TRUPULSE™ Generator

Interventions

  • DeviceDual Energy THERMOCOOL SMARTTOUCH™ SF (STSF) Bi-Directional Navigation catheter with TRUPULSE™ Generator

    The THERMOCOOL SMARTTOUCH™ SF Bi-Directional Navigation Catheter is an irrigated, contact-force-sensing catheter used to map the heart and deliver radiofrequency (RF) or pulsed-field (PF) energy to selected treatment sites. The catheter is connected to the TRUPULSE™ Generator, which provides both energy types, and to the nGEN™ Pump, which controls saline irrigation. The system is used with the CARTO™ 3 electroanatomic mapping system and workstation with the VISITAG SURPOINT™ Module to display heart anatomy, catheter location, catheter-to-tissue contact, and treatment information during the procedure.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Successful Delivery of Ablation Lesions Using the Dual-Energy THERMOCOOL SMARTTOUCH SF Catheter With the TRUPULSE Generator

    Feasibility is defined as successful delivery of ablation energy at the targeted premature ventricular complex (PVC) site. Delivery counts as successful only if there is no study device deficiency or malfunction that prevents energy delivery, and no need to convert to a bailout ablation approach.

    Time frame: During the index ablation procedure

Secondary outcomes

  1. Acute procedural success

    Number of participants with elimination of the target premature ventricular contraction by the end of the procedure.

    Time frame: End of the ablation procedure

  2. Participants with greater than 80% reduction in target PVC burden

    Number of participants with greater than 80% reduction from baseline in the burden of the target premature ventricular contraction on Holter monitoring.

    Time frame: 1 month, 6 months

  3. Change in Short Form Health Survey (SF-36) score

    The 36-Item Short Form Health Survey (SF-36) is a participant-reported questionnaire that assesses health-related quality of life across eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Total scores range from 0 to 100. Higher scores indicate better health status.

    Time frame: Baseline, 1 month, 6 months

  4. Change in EQ-5D score

    The EQ-5D is a participant-reported measure of health-related quality of life covering five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses across the five dimensions define the participant's health state. Higher scores indicate better health.

    Time frame: Baseline, 1 month, 6 months

  5. Number of Participants With New Coronary Artery Stenosis on Coronary CT Angiography at 6 Months After Ablation

    Total number of patients with new-onset coronary luminal stenosis found on CT coronary angiography

    Time frame: 6 months

  6. Total Procedure Time

    Total procedure time will be reported in minutes

    Time frame: From start to finish of index ablation procedure

  7. Electrogram endpoints

    EGM amplitude changes after PF, RF, and RF-PF lesion delivery

    Time frame: Intraprocedure

  8. Ablation Lesion Depth

    Maximum depth of the ablation lesion at the target premature ventricular complex (PVC) site. Depth is measured from the endocardial surface on late gadolinium enhancement (LGE) cardiac MRI. Only participants with an evaluable post-ablation MRI are analyzed. Reported in millimeters.

    Time frame: 1 month and 6 months after ablation

  9. Ablation Lesion Width

    Maximum width of the ablation lesion at the target PVC site, measured on LGE cardiac MRI. Only participants with an evaluable post-ablation MRI are analyzed. Reported in millimeters.

    Time frame: 1 month and 6 months after ablation

  10. Ablation Lesion Volume

    Total volume of the ablation lesion at the target PVC site, measured on LGE cardiac MRI. Only participants with an evaluable post-ablation MRI are analyzed. Reported in cubic centimeters.

    Time frame: 1 month and 6 months after ablation

  11. Number of Radiofrequency (RF) Lesions Delivered per Participant

    Total number of RF lesions delivered with the study catheter during the index procedure

    Time frame: During the index ablation procedure

  12. Number of Pulsed-Field (PF) Lesions Delivered per Participant

    Total number of PF lesions delivered with the study catheter during the index procedure

    Time frame: During the index ablation procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 32 interventional studies with no phase under Ventricular Premature Complexes, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 52. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Nov 13, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2029
CompletionEst.
Jun 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07935265
Lead sponsor
Konstantinos Siontis
Responsible party
Konstantinos Siontis (Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Nov 13, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Konstantinos Siontis, MD
Contact
siontis.konstantinos@mayo.edu
507-255-0774
Konstantinos Siontis, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion